The company has sought FDA approval to expand the use of its hepatitis Bvaccine Heplisav-B for adults on hemodialysis and a decision is due onMay 13, 2024.
The Heplisav-B vaccine, which combines hepatitis B surface antigen withDynavax's proprietary Toll-like Receptor (TLR) 9 agonist adjuvant CpG1018, was approved by the FDA in November 2017, for prevention ofinfection caused by all known subtypes of hepatitis B virus in adults ofage 18 years and older.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.